During Diffusion Pharmaceutical’s preclinical studies in rats, glioblastoma cells were surgically implanted in the brains and the rats were then divided into three groups. In the control group (group of rats which did NOT receive any treatment) all the rats died within 29 days. In the second group, which received radiation therapy at 10 days post tumor implantation but not TSC, 28% were alive at 60 days. In the third treatment group, which received an IV injection of TSC prior to radiation therapy, survival increased to 73%.
(Sheehan J, et al. Trans sodium crocetinate sensitizes glioblastoma multiforme tumors to radiation. J Neurosurg 108:972-978, 2008. See also, Sheehan J, et al, TSC with Radiation and Temozolomide; J Neurosurg 113:234-239, 2010.)
At 60 days, complete tumor remission was seen in the survivors of the “radiation therapy plus TSC” group, whereas tumor regrowth was observed in survivors in the “radiation therapy alone” group.